Cargando…
Views of European Drug Development Stakeholders on Treatment Optimization and Its Potential for Use in Decision-Making
BACKGROUND: The current drug development paradigm has been criticized for being too drug-centered and for not adequately focusing on the patients who will eventually be administered the therapeutic interventions it generates. The drug-driven nature of the present framework has led to the emergence o...
Autores principales: | Saesen, Robbe, Lejeune, Stéphane, Quaglio, Gianluca, Lacombe, Denis, Huys, Isabelle |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7015135/ https://www.ncbi.nlm.nih.gov/pubmed/32116718 http://dx.doi.org/10.3389/fphar.2020.00043 |
Ejemplares similares
-
How do cancer clinicians perceive real-world data and the evidence derived therefrom? Findings from an international survey of the European Organisation for Research and Treatment of Cancer
por: Saesen, Robbe, et al.
Publicado: (2022) -
Past, Current, and Future Cancer Clinical Research Collaborations: The Case of the European Organisation for Research and Treatment of Cancer
por: Broes, Stefanie, et al.
Publicado: (2020) -
Characteristics of Early Phase Clinical Trials for Rare Cancers: Insights From Interviews With Stakeholders
por: Dooms, M, et al.
Publicado: (2022) -
Involvement of the European Medicines Agency in multi-stakeholder regulatory science research projects: experiences of staff members and project coordinators
por: Saesen, Robbe, et al.
Publicado: (2023) -
Analysis of the characteristics and the degree of pragmatism exhibited by pragmatic-labelled trials of antineoplastic treatments
por: Saesen, Robbe, et al.
Publicado: (2023)